Rhizen is Swiss HQ biotech focused on discovery and development of innovative, small molecule drugs for the treatment of cancer & inflammatory diseases. We have demonstrated our leadership of the PI3K space through our discovery of Umbralisib & Tenalisib - class leading PI3K isoform-specific inhibitors that are poised to transform the NHL & CLL space. We have a deep pipeline of novel differentiated assets across various stages of development.